高同型半胱氨酸血症和类风湿关节炎的关系

正同型半胱氨酸(Hcy)是一种含硫非必需氨基酸,同型半胱氨酸代谢酶的活性受损,叶酸、维生素B6、B12的缺乏等因素使人体内Hcy水平升高形成高同型半胱氨酸血症(HHcy)。Hcy升高可以激活类风湿关节炎(RA)患者的免疫系统,而免疫炎性反应可能导致HHcy,其可以促进RA患者动脉粥样硬化的发生,是动脉粥样硬化的独立危险因素。RA是一种导致多关节功能障碍的炎症性自身免疫性疾病。近年发现,因心血     

高同型半胱氨酸血症的神经毒性机制研究进展

高同型半胱氨酸血症(HHcy)是由同型半胱氨酸(Hcy)代谢异常引起的。HHcy既是心脑血管疾病的独立危险因素,也与多种神经退行性疾病和精神疾病密切相关。HHcy主要通过血管和神经毒性发挥致病作用。本文就近年来HHcy的致神经毒性作用的机制做一综述。     

同型半胱氨酸与糖尿病大血管并发症的关系

同型半胱氨酸(homocysteine，Hcy)是一种反应性血管损伤氨基酸，高Hcy血症是心脑血管等疾病的独立危险因素。近几年来，人们发现Hcy与糖尿病也有关，高Hcy血症可能是糖尿病大、小血管并发症发生、发展的一个重要因素。     

高同型半胱氨酸血症与周围神经病变

近年来研究认为同型半胱氨酸是一种反应性血管损伤氨基酸，并与多种疾病相关。HHS（Hordaland Homocysteine Study）研究结果表明：高同型半胱氨酸血症可增加心血管疾病的发病率及死亡率；血浆Hcy水平增高的成年人更易罹患抑郁症及认知功能障碍；在女性人群中，Hcy与骨密度减低、骨质疏松及妊娠相关疾病有关。Hhcy为糖尿病及其大血管和微血管并发症的危险因素。对高同型半胱氨酸血症发病机制及其与各种疾病相关性的研究已经成为热点课题。     

脑梗死患者血浆总同型半胱氨酸与血栓调节蛋白的关系研究

同型半胱氨酸 (homocysteine ,Hcy)是蛋氨酸代谢产生的一种中间产物。目前认为高同型半胱氨酸血症的发病原因有遗传和营养两种因素。近年来 ,关于高同型半胱氨酸血症与心血管、脑血管和周围血管之间的关系进行了大量的实验研究、临床流行病学和营养学研究 ,广泛认为Hcy升高可能是独立于闭塞性血管疾病其它传统危险因素的一个重要因素[1] ;血栓调节蛋白 (thrombomodulin ,TM )是存在于内皮细胞 (endothelialcell,EC)表面的一种糖蛋白 ,主要功能是抗血栓形成。目前 ,国内外学者关于脑梗死时血浆总同型半胱氨酸 (totalhomocysteine ,tH cy)…     

“同型半胱氨酸”与疾病

Hcy是蛋氨酸代谢的中间产物，参与体内一碳单位的转移，它作为机体内一种正常的生理物质，对体内许多代谢反应和某些物质生理功能的发挥具有重要作用。许多研究显示，高同型半胱氨酸血症在动脉粥样硬化和血栓栓塞性疾病如脑血管病、冠心病和静脉血栓等的发病机制中起重要作用，已被认为是独立的危险因素之一。本文对高同型半胱氨酸（Hyperhomocysteinemia，HHcy）与疾病的关系作一综述。主要包括Hcy的认识历史、Hcy与相关疾病的关系、Hcy检测及影响因素、作用机制及HHcy的防治等。     

血清同型半胱氨酸、肌酸激酶在脑血管疾病中的变化及临床意义

大量流行病学资料发现,高同型半胱氨酸（Hey）血症是心脑血管疾病发病的独立危险因子,阐明高Hcy血症发病机制和防治高Hcy血症对控制心脑血管疾病具有重要意义。血清肌酶激酶（CK）是一种细胞内酶,在骨组织、心肌和脑组织中含量丰富。我们对105例脑血管疾病患者和87名正常对照人群的血Hcy、CK进行了检测,以探讨脑血管疾病患者血Hcy、CK的变化及其临床意义。     

同型半胱氨酸对人血管平滑肌细胞凋亡及凋亡相关蛋白表达的影响

高同型半胱氨酸血症是动脉粥样硬化（AS）性血管疾病形成的独立危险因素,但其机制至今不完全清楚。起初,人们大都致力研究于同型半胱氨酸（Hcy）对内皮细胞的毒性作用,发现Hcy可损害内皮细胞,影响其舒张功能,近年来,     

高同型半胱氨酸血症与静脉血栓形成

轻到中度的高同型半胱氨酸血症（HHcy)是心血管疾病的一个独立危险因子。目前大部分研究认为。HHcy也是静脉血栓形成的危险因子,但仍存在争议。本文对同型半胱氨酸（Hcy)的代谢及其影响因素,HHcy与静脉血栓形成的关系,以及HHcy促进血栓形成的机制等进行综述。     

荧光偏振免疫法测定血同型半胱氨酸在临床中的应用

同型半胱氨酸（homocystein,Hcy）又称为高半胱氨酸,是一种含硫基氨基酸,是蛋氨酸代谢过程中的一个重要中间产物、B族维生素（包括叶酸,VB12,VB6等）是代谢中必要的辅助因子。高同型半胱氨酸血症（hyperhomocysteinemia．Hhcy），对于冠状动脉疾病、脑血管疾病和末梢血管性疾病。是一个非常有效、独立的危险性指标。     

Association between homocysteine, vitamin B(6) concentrations and inflammation.

During the last years, a growing body of evidence has been accumulated on the role of hyperhomocysteinemia in the occurrence of coronary artery disease and other arterial occlusive diseases. The mechanism by which high circulating homocysteine concentrations are a risk factor for atherothrombosis is incompletely understood. The present review is aimed to evaluate the role of inflammation in influencing homocysteine (Hcy) and vitamin B(6) concentrations. Results of a large population-based study have suggested that inflammatory markers are the major determinants of Hcy and vitamin B(6) concentrations. This association, independent of the leading factor, may explain, at least in part, why subjects with high concentrations of Hcy and low concentrations of vitamin B(6) have a high risk of developing cardiovascular diseases.     

肾功能损害对血浆同型半胱氨酸浓度的影响

目的研究不同肾功能患者血浆同型半胱氨酸(Hcy)浓度的变化特点及其与血浆肌酐和栓塞性心脑血管疾病(CVD)的关系,探讨其临床意义。方法采用快速高压液相微柱层析法测定中国人民解放军第455医院肾内科98例不同阶段慢性肾衰竭(CRF)患者及40例正常人的血浆Hcy浓度。结果CRF患者高Hcy血症的发生率高达86.7%,为正常对照组的33.3倍,P<0.01;并且血浆Hcy的浓度随着血肌酐浓度的升高或内生肌酐清除率(Ccr)的降低而升高,有明显的相关性,P<0.01。血液透析后(Post-HD)血浆Hcy水平较血液透析前(Pre-HD)下降约34.1%,但仍显著高于正常人,P<0.01。伴有栓塞性CVD组的血浆Hcy较无此病史者明显升高,P<0.01。结论不同阶段的CRF患者普遍存在高Hcy血症,并且肾功能损害的程度与Hcy浓度明显相关,CRF患者的高Hcy血症可能与其CVD有关。     

MTHFR基因型与晚期肾脏病/肾移植受者血浆高半胱氨酸水平及心血管病发生率的关系

目的 探讨血浆高半胱氨酸(Hcy)在肾脏病患者发生心血管疾患中的影响。方法 采用荧光偏振免疫分析、DNA基因型别分析等技术,对50例晚期肾脏病患者及肾移植受者进行了Hcy水平、N5,N10-亚甲基四氢叶酸还原酶(MTHFR)基因多态性分布测定及相关分析,并与肾病综合征患者及正常人进行对照。结果 (1)受检人群中Hcy水平较正常人及肾病综合征患者组明显升高;(2)受检人群中MTHFR的TT突变机率较正常人及肾病综合征组明显升高;(3)TT基因型与Hcy水平升高及心血管疾患的发生机率密切相关。结论 血浆中的Hcy可能是晚期肾脏病患者和肾移植受者体内的一种重要毒性物质。受检人群中MTHFR的高频率TT突变可能与血浆Hcy的水平升高有关。     

Controlled “off–on” fluorescent probe for the specific detection of hyperhomocysteinemia

Hyperhomocysteinemia is an established risk factor for atherosclerosis and vascular disease. Therefore, designing a hyperhomocysteinemia specific probe is of great significance for the early warning of cardiovascular diseases. However, developing probes that can efficiently and specifically recognize homocysteine (Hcy) remains a tremendous challenge. Therefore, we designed an Hcy-specific fluorescent probe (HSFP) with excellent selectivity and anti-interference capability. Interestingly, this probe can automatically “off–on” in water solution, but the fluorescence of HSFP remains “off” when Hcy is present in the solution. The spectroscopic data demonstrated that the fluorescence of HSFP attenuated 13.8 folds toward Hcy in water without interference from other biothiols and amino acids. Furthermore, HSFP can sensitively reflect the change of Hcy content in cells. Therefore, HSFP was further applied to detect hyperhomocysteinemia in vivo with high efficiency. In summary, we have developed an Hcy-specific fluorescent probe to efficiently detect Hcy in vivo and in vitro, which may contribute to basic or clinical research.

An Hcy-specific fluorescent probe (HSFP) with excellent selectivity and anti-interference capability was developed for the detection of hyperhomocysteinemia.     

Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake?

Hyperhomocysteinemia is considered as a risk factor for cardiovascular diseases. Usually, an inverse relationship exists between homocysteine and folate levels, and supplementation with folate lowers homocysteine concentrations in patients. Therefore, hyperhomocysteinemia is mainly ascribed to the insufficient dietary intake of folate. Hyperhomocysteinemia has also been observed in infections and inflammatory diseases. Oxidative stress appears to be involved in the pathogenesis of these disorders, and associations have been found between homocysteine and e.g., neopterin concentration. Increased neopterin concentration indicates immune system activation and also allows an estimate of thus elicited oxidative stress. It may be relevant that the active cofactor, tetrahydrofolate, is very susceptible to oxidation. Immunologically induced oxidative stress could lead to folate depletion resulting in hyperhomocysteinemia. Thus, hyperhomocysteinemia in patients can be considered as an indirect consequence of hyperconsumption of antioxidant vitamins during prolonged states of immune activation.     

The molecular basis of homocysteine thiolactone-mediated vascular disease.

Accumulating evidence suggests that a metabolite of homocysteine (Hcy), the thioester Hcy-thiolactone, plays an important role in atherogenesis and thrombosis. Hcy-thiolactone levels are elevated in hyperhomocysteinemic humans and mice. The thioester chemistry of Hcy-thiolactone underlies its ability to form isopeptide bonds with protein lysine residues, which impairs or alters the protein's function. Protein targets for the modification by Hcy-thiolactone in human blood include fibrinogen, low-density lipoprotein, and high-density lipoprotein. Protein N-homocysteinylation leads to pathophysiological responses, including increased susceptibility to thrombogenesis caused by N-Hcy-fibrinogen, and an autoimmune response elicited by N-Hcy-proteins. Chronic activation of these responses in hyperhomocysteinemia over many years could lead to vascular disease. This article reviews recent evidence supporting the hypothesis that Hcy-thiolactone contributes to pathophysiological effects of Hcy on the vascular system.     

Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker

Plasma homocysteine (Hcy), a well-known independent risk factor for coronary heart disease, is also a risk factor for cancer. Results from our studies indicate that Hcy could be used as a tumor marker. We found elevated circulating total homocysteine (tHcy) in cancer patients even though they were not treated with anti-folate drugs. In serial specimens from cancer patients undergoing treatment, the change of tHcy coincided with the concentration of tumor markers. The rapid proliferation of tumor cells contributed to the much higher concentrations of circulating tHcy. Both concentrations of tHcy and tumor marker would increase in parallel during the growth of tumor cell, but only the Hcy concentration would decline in response to tumor cell death. Several biochemical changes, including folate deficiency, oxidative stress, aberrant DNA methylation, and production of homocysteine thiolactone have been identified in association with hyperhomocysteinemia, which explained why elevated homocysteine eventually led to carcinogenesis. Conceivably, tHcy may be used as a more accurate tumor marker for monitoring cancer patients during treatment, and hyperhomocysteinemia as a risk factor for carcinogenesis.     

脑血管病高Hcy血症与维生素B12和叶酸的相关性研究

目的：研究脑血管病患者的高同型半胱氨酸（Hcy）血症与血清维生素B12（VitB12）和叶酸（FA）水平的相关性。方法：采用酶法检测171例脑血管病患者和76例健康体检志愿的血清Hcy水平,用化学发光方法检测其血清FA和VitB12水平。结果：脑血管病组患者血清Hcy水平明显高于对照组（P＆lt;0.01）,其中脑梗死组患者的血清Hcy水平明显高于脑出血组（P＆lt;0.01）;而对照组的血清FA和VitB12水平明显高于脑血管病组（P＆lt;0.01）;脑血管病组患者血清的Hcy水平与其血清VitB12和FA的水平呈负相关（r1=-0.82,r2=-0.86）。结论：血浆Hcy水平升高与脑血管病的发病密切相关,是脑血管病的独立危险因素,而血清中的FA和VitB12的下降可能为导致高同型半胱氨酸血症的关键因素之一。     

成年人群血清胱抑素C与同型半胱氨酸水平升高的疾病谱分析

目的 探讨并分析成年人群血清胱抑素C(Cys-C)和同型半胱氨酸(Hcy)升高的疾病谱.方法 选取空军特色医学中心711例住院和门诊患者,于Beckman AU2700全自动生化分析仪上同时检测Cys-C和Hcy,检测方法分别为免疫比浊法和循环酶法;采用回顾性分析的方法统计所有人群的疾病诊断信息,按照高血压、肿瘤、心脑...